NASDAQ:VCELVericel Stock Price, Forecast & News

Vericel's stock was trading at $12.08 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, VCEL stock has increased by 19.0% and is now trading at $14.38. View which stocks have been most impacted by Coronavirus.

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Vericel in the last year. There are currently 1 hold rating and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Vericel.

Vericel is scheduled to release its next quarterly earnings announcement on Tuesday, August 4th 2020. View our earnings forecast for Vericel.

Vericel Corp (NASDAQ:VCEL) released its quarterly earnings data on Tuesday, May, 5th. The biotechnology company reported ($0.10) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.08) by $0.02. The biotechnology company had revenue of $26.70 million for the quarter, compared to analysts' expectations of $26.23 million. Vericel had a negative net margin of 9.39% and a positive return on equity of 5.87%. Vericel's revenue for the quarter was up 22.5% on a year-over-year basis. During the same period last year, the firm earned ($0.07) earnings per share. View Vericel's earnings history.

Vericel updated its first quarter 2020 IntraDay earnings guidance on Thursday, April, 2nd. The company provided EPS guidance of for the period. The company issued revenue guidance of $26.39-26.39 million, compared to the consensus revenue estimate of $26.61 million.

5 analysts have issued twelve-month target prices for Vericel's stock. Their forecasts range from $21.00 to $32.00. On average, they anticipate Vericel's stock price to reach $24.25 in the next twelve months. This suggests a possible upside of 68.6% from the stock's current price. View analysts' price targets for Vericel.

News articles about VCEL stock have been trending positive on Monday, according to InfoTrie Sentiment Analysis. The research firm ranks the sentiment of news coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Vericel earned a media sentiment score of 2.8 on InfoTrie's scale. They also gave news stories about the biotechnology company a news buzz of 10.0 out of 10, meaning that recent news coverage is extremely likely to have an impact on the company's share price in the near term. View the latest news aboutVericel.

Some companies that are related to Vericel include Alector (ALEC), Fate Therapeutics (FATE), Bill.com (RVMD), Adverum Biotechnologies (ADVM), SpringWorks Therapeutics (SWTX), Sangamo Therapeutics (SGMO), Twist Bioscience (TWST), Mesoblast (MESO), Editas Medicine (EDIT), Adaptimmune Therapeutics (ADAP), Regenxbio (RGNX), I-Mab (BDTX), Cortexyme (CRTX), Coherus Biosciences (CHRS) and Beam Therapeutics (BEAM). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Vericel investors own include Exelixis (EXEL), Momo (MOMO), Novavax (NVAX), Amarin (AMRN), Synergy Pharmaceuticals (SGYP), Dynavax Technologies (DVAX), NVIDIA (NVDA), Verastem (VSTM), Sorrento Therapeutics (SRNE) and TG Therapeutics (TGTX).

Vericel trades on the NASDAQ under the ticker symbol "VCEL."

Vericel's stock is owned by many different institutional and retail investors. Top institutional investors include BlackRock Inc. (7.51%), Waddell & Reed Financial Inc. (7.24%), State Street Corp (3.96%), UBS Group AG (3.28%), Wells Fargo & Company MN (2.15%) and Nuveen Asset Management LLC (1.74%). Company insiders that own Vericel stock include Dominick Colangelo, Gerard J Michel, Michael Halpin, Paul K Wotton and Steven C Gilman. View institutional ownership trends for Vericel.

VCEL stock was sold by a variety of institutional investors in the last quarter, including Morgan Stanley, Emerald Mutual Fund Advisers Trust, First Washington CORP, Fort Washington Investment Advisors Inc. OH, Calamos Advisors LLC, Russell Investments Group Ltd., Parametric Portfolio Associates LLC, and AQR Capital Management LLC. Company insiders that have sold Vericel company stock in the last year include Dominick Colangelo, Gerard J Michel, and Michael Halpin. View insider buying and selling activity for Vericel.

VCEL stock was purchased by a variety of institutional investors in the last quarter, including UBS Group AG, Waddell & Reed Financial Inc., Granahan Investment Management Inc. MA, Silvercrest Asset Management Group LLC, Soleus Capital Management L.P., Wells Fargo & Company MN, BlackRock Inc., and Millrace Asset Group Inc.. View insider buying and selling activity for Vericel.

Shares of VCEL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of VCEL stock can currently be purchased for approximately $14.38.

Vericel has a market capitalization of $648.68 million and generates $117.85 million in revenue each year. The biotechnology company earns $-9,660,000.00 in net income (profit) each year or $0.18 on an earnings per share basis. Vericel employs 216 workers across the globe.

The official website for Vericel is www.vcel.com.

Vericel's mailing address is 64 SIDNEY STREET, CAMBRIDGE MA, 02139. The biotechnology company can be reached via phone at 617-588-5555 or via email at [email protected]